Skip to main content

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.75
+4.48 (2.18%)
AAPL  272.50
+6.32 (2.37%)
AMD  214.22
+17.62 (8.96%)
BAC  50.38
-0.69 (-1.35%)
GOOG  311.28
-0.41 (-0.13%)
META  639.54
+2.29 (0.36%)
MSFT  386.25
+1.78 (0.46%)
NVDA  193.53
+1.98 (1.03%)
ORCL  145.21
+3.90 (2.76%)
TSLA  404.86
+5.03 (1.26%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.